This led us to propose that cyclooxygenase (cox)-inhibitors or other inhibitors of the cAMP signaling pathway might improve DNA damage-based therapy of BCP-ALL by sustaining p53-mediated apoptosis [27]. Here, TP53 is linked to acute lymphoblastic leukemia.